Notably, AR is the target of the drug Enzalutamide, which is indicated for men with an advanced stage of the disease (Scott, 2018), or that MYC is the target of BET bromodomain inhibitors and are generally effective in castration-resistant prostate cancer cases (Coleman et al., 2019). This evidence concerns the gene MYC and prostate cancer.